pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Fig. 4.
Fig. 4.
Safety of erenumab in the three clinical trials. A. Discontinuation; B. Incidence of severe adverse events; C. Incidence of adverse events.
Korean J Clin Pharm 2019;29:71-8 https://doi.org/10.24304/kjcp.2019.29.2.71
© 2019 Korean J Clin Pharm